Remy Durand - May 8, 2024 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC. (ALPN)

Role
Chief Business Officer
Signature
/s/ James Paul Rickey, attorney-in-fact
Stock symbol
ALPN
Transactions as of
May 8, 2024
Transactions value $
$513,869
Form type
4
Date filed
5/10/2024, 07:25 PM
Previous filing
Jan 5, 2024
Next filing
May 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALPN Common Stock Options Exercise $130K +9.85K +25.84% $13.20 47.9K May 8, 2024 Direct F1
transaction ALPN Common Stock Options Exercise $163K +25K +52.14% $6.51 72.9K May 8, 2024 Direct
transaction ALPN Common Stock Options Exercise $50.6K +12.4K +16.95% $4.09 85.3K May 8, 2024 Direct
transaction ALPN Common Stock Options Exercise $123K +38.1K +44.63% $3.23* 123K May 8, 2024 Direct
transaction ALPN Common Stock Options Exercise $47.6K +10K +8.1% $4.76 133K May 8, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALPN Stock Option (Right to buy) Options Exercise $0 -9.85K -12.31% $0.00 70.2K May 8, 2024 Common Stock 9.85K $13.20 Direct F2, F3
transaction ALPN Stock Option (Right to buy) Options Exercise $0 -25K -100% $0.00* 0 May 8, 2024 Common Stock 25K $6.51 Direct F2, F4
transaction ALPN Stock Option (Right to buy) Options Exercise $0 -12.4K -82.43% $0.00 2.64K May 8, 2024 Common Stock 12.4K $4.09 Direct F2, F5
transaction ALPN Stock Option (Right to buy) Options Exercise $0 -38.1K -58.58% $0.00 26.9K May 8, 2024 Common Stock 38.1K $3.23 Direct F2, F6
transaction ALPN Stock Option (Right to buy) Options Exercise $0 -10K -100% $0.00* 0 May 8, 2024 Common Stock 10K $4.76 Direct F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024.
F2 The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F3 One-fourth (1/4) of the shares subject to the option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
F4 One-fourth (1/4) of the shares subject to the option will vest on February 6, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
F5 One-fourth (1/4) of the shares subject to the option will vest on May 1, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
F6 One-fourth (1/4) of the shares subject to the option will vest on January 23, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.
F7 One-fourth (1/4) of the shares subject to the option will vest on October 8, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date.